Bronchiectasis - Pipeline Review, H2 2014

Published: Aug, 2014 | Pages: 83 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Bronchiectasis - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Bronchiectasis - Pipeline Review, H2 2014', provides an overview of the Bronchiectasis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Bronchiectasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bronchiectasis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Bronchiectasis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Bronchiectasis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Bronchiectasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Bronchiectasis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Bronchiectasis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Bronchiectasis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Bronchiectasis Overview 8
Therapeutics Development 9
Pipeline Products for Bronchiectasis - Overview 9
Pipeline Products for Bronchiectasis - Comparative Analysis 10
Bronchiectasis - Therapeutics under Development by Companies 11
Bronchiectasis - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Unknown Stage Products 16
Bronchiectasis - Products under Development by Companies 17
Bronchiectasis - Companies Involved in Therapeutics Development 19
GlaxoSmithKline plc 19
Grifols, S.A. 20
Chiesi Farmaceutici SpA 21
Zambon Company S.p.A. 22
Bayer AG 23
Kamada Ltd. 24
Nostrum Pharmaceuticals, LLC 25
Pulmatrix, Inc. 26
Edmond Pharma Srl 27
Savara Inc. 28
Clarassance, Inc. 29
Alitair Pharmaceuticals, Inc. 30
Serendex Pharmaceuticals A/S 31
Bronchiectasis - Therapeutics Assessment 32
Assessment by Monotherapy Products 32
Assessment by Target 33
Assessment by Mechanism of Action 35
Assessment by Route of Administration 37
Assessment by Molecule Type 39
Drug Profiles 41
ARD-3150 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
ciprofloxacin - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
alpha-1-proteinase inhibitor (human) - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
BAY-858501 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
vancomycin - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
GSK-2793660 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
erdosteine - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
CG-1011 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Small Molecules to Inhibit Neutrophil Elastases - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
PUR-0400 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
dapsone - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
ALT-07 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Recombinant Human Follistatin - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
sargramostim - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
ALT-09 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
PUR-1000 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
ZP-044 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Bronchiectasis - Recent Pipeline Updates 66
Bronchiectasis - Dormant Projects 72
Bronchiectasis - Discontinued Products 73
Bronchiectasis - Product Development Milestones 74
Featured News & Press Releases 74
Jun 23, 2014: Aradigm Corporation Announces the Dosing of the First Patient in Phase III Study of Pulmaquin in Non-Cystic Fibrosis Bronchiectasis (ORBIT-4) 74
Jun 03, 2014: Aradigm Receives $5 Million Milestone For Dosing of the First Patient in Phase III Study of Pulmaquin in Non-Cystic Fibrosis Bronchiectasis 75
May 20, 2014: FDA Grants QIDP Designation to Aradigm's Inhaled Antibiotic 76
May 05, 2014: Pulmatrix Presents Preclinical Data on iSPERSE Inhaled Antibiotics at the 2014 Respiratory Drug Delivery Conference 77
Apr 28, 2014: Erdosteine Received Orphan Drug Status by the FDA 77
Jan 07, 2014: Alitair Receives Orphan Drug Designation for Erdosteine in Bronchiectasis 78
Aug 01, 2013: Aradigm Awarded NIH Grant to Investigate the Treatment of Pulmonary Non-Tuberculous Mycobacterial Infections with Pulmaquin and Lipoquin 78
Jun 24, 2013: Kamada Receives Two Key Patents Covering Its New Alpha-1 Antitrypsin Product 79
Apr 24, 2013: Pharmaxis's Phase III Clinical Trial With Bronchitol Fails To Meet Primary Endpoint 80
Mar 08, 2013: Pharmaxis Announces Completion Of Phase III Trial Of Bronchitol For Treatment Of Bronchiectasis 81
Appendix 82
Methodology 82
Coverage 82
Secondary Research 82
Primary Research 82
Expert Panel Validation 82
Contact Us 83
Disclaimer 83

List of Tables
Number of Products under Development for Bronchiectasis, H2 2014 9
Number of Products under Development for Bronchiectasis - Comparative Analysis, H2 2014 10
Number of Products under Development by Companies, H2 2014 12
Comparative Analysis by Late Stage Development, H2 2014 13
Comparative Analysis by Clinical Stage Development, H2 2014 14
Comparative Analysis by Early Stage Development, H2 2014 15
Comparative Analysis by Unknown Stage Development, H2 2014 16
Products under Development by Companies, H2 2014 17
Products under Development by Companies, H2 2014 (Contd..1) 18
Bronchiectasis - Pipeline by GlaxoSmithKline plc, H2 2014 19
Bronchiectasis - Pipeline by Grifols, S.A., H2 2014 20
Bronchiectasis - Pipeline by Chiesi Farmaceutici SpA, H2 2014 21
Bronchiectasis - Pipeline by Zambon Company S.p.A., H2 2014 22
Bronchiectasis - Pipeline by Bayer AG, H2 2014 23
Bronchiectasis - Pipeline by Kamada Ltd., H2 2014 24
Bronchiectasis - Pipeline by Nostrum Pharmaceuticals, LLC, H2 2014 25
Bronchiectasis - Pipeline by Pulmatrix, Inc., H2 2014 26
Bronchiectasis - Pipeline by Edmond Pharma Srl, H2 2014 27
Bronchiectasis - Pipeline by Savara Inc., H2 2014 28
Bronchiectasis - Pipeline by Clarassance, Inc., H2 2014 29
Bronchiectasis - Pipeline by Alitair Pharmaceuticals, Inc., H2 2014 30
Bronchiectasis - Pipeline by Serendex Pharmaceuticals A/S, H2 2014 31
Assessment by Monotherapy Products, H2 2014 32
Number of Products by Stage and Target, H2 2014 34
Number of Products by Stage and Mechanism of Action, H2 2014 36
Number of Products by Stage and Route of Administration, H2 2014 38
Number of Products by Stage and Molecule Type, H2 2014 40
Bronchiectasis Therapeutics - Recent Pipeline Updates, H2 2014 66
Bronchiectasis - Dormant Projects, H2 2014 72
Bronchiectasis - Discontinued Products, H2 2014 73